Trade Names:Bicalutamide- Tablets 50 mg
Trade Names:Casodex- Tablets 50 mgCO Bicalutamide (Canada)Novo-Bicalutamide (Canada)PMS-Bicaltamide (Canada)ratio-Bicalutamide (Canada)Sandoz Bicalutamide (Canada)
Bicalutamide inhibits the action of androgens.
Well absorbed. T max is 31.3 h (active isomer). C max is 0.77 mcg/mL (active isomer).
96% protein bound.
Undergoes stereospecific metabolism. The S-isomer (inactive) is metabolized by glucuronidation. The R-isomer (active) undergoes glucuronidation but is predominantly oxidized to an inactive metabolite.
Eliminated in urine and feces; half-life is 5.8 days (active isomer).
No dosage adjustment is necessary.Hepatic Function Impairment
The half-life of the R-isomer is increased about 76% in patients with severe liver disease. No dosage adjustment is necessary.
Stage D 2 metastatic carcinoma of the prostate in combination with a luteinizing hormone–releasing hormone (LHRH) analog.
Women; pregnancy; hypersensitivity to the drug or any of the tablet components.
PO 50 mg (1 tablet) once daily at the same time of day with or without food.
Store tablets at controlled room temperature (68° to 77°F).
Mean midazolam C max increased 1.5-fold and AUC increased 1.9-fold when given with bicalutamide. Use caution when coadministered with CYP3A4 substrates.Warfarin
PT may increase when bicalutamide is initiated in patients stabilized on long-term warfarin therapy.
None well documented.
Hot flashes (53%); hypertension (8%); angina pectoris, CHF, coronary artery disease, heart arrest, MI, syncope (2% to 5%).
Asthenia (22%); dizziness (10%); paresthesia (8%); headache, insomnia (7%); anxiety (5%); depression (4%); confusion, hypertonia, libido decreased, nervousness, neuropathy, somnolence (2% to 5%).
Rash (9%); sweating (6%); alopecia, dry skin, herpes zoster, pruritus, skin carcinoma, skin disorder (2% to 5%).
Constipation (22%); nausea (15%); diarrhea (12%); abdominal pain (11%); dyspepsia, liver enzymes increased (7%); anorexia, flatulence, vomiting (6%); dry mouth, dysphagia, GI carcinoma, GI disorder, melena, periodontal abscess, rectal hemorrhage (2% to 5%).
Hematuria, nocturia (12%); gynecomastia, UTI (9%); impotence (7%); breast pain, urinary frequency (6%); impaired urination, urinary retention (5%); urinary incontinence (4%); dysuria, hydronephrosis, urinary tract disorder, urinary urgency (2% to 5%).
Peripheral edema (13%); weight loss (7%); hyperglycemia (6%); alkaline phosphatase increased, weight gain (5%); BUN increased, creatinine increased, dehydration, edema, gout, hypercholesterolemia (2% to 5%).
Back pain (25%); bone pain (9%); myasthenia (7%); arthritis (5%); pathological fracture (4%); leg cramps, myalgia (2% to 5%).
Dyspnea (13%); cough increased, pharyngitis (8%); bronchitis (6%); pneumonia, rhinitis (4%); asthma, epistaxis, lung disorder, sinusitis (2% to 5%); interstitial lung disease, including interstitial pneumonitis and pulmonary fibrosis (postmarketing).
General pain (35%); pelvic pain (21%); infection (18%); anemia (11%); chest pain (8%); flu syndrome (7%); cataract specified, chills, cyst, fever, hernia, neck pain, neoplasm, sepsis (2% to 5%).
Regularly monitor prostate-specific antigen and evaluate for clinical progression if levels rise. Measure serum transaminase levels prior to starting bicalutamide, at regular intervals for the first 4 mo, and periodically thereafter. Discontinue if patient develops jaundice or if ALT rises above 2 times the ULN.
Category X .
Bicalutamide is not indicated for use in women.
Safety and efficacy not established.
Reactions, including angioneurotic edema and urticaria, have been reported.
Use bicalutamide with caution in patients with moderate to severe hepatic function impairment.
Administration of bicalutamide may lead to inhibition of spermatogenesis. Long-term effects are not known.
Somnolence has been reported during treatment with bicalutamide. Advise patients to use caution when driving or operating machinery.
Reduction in glucose tolerance reported in men receiving LHRH agonists. Consider monitoring blood glucose in patients receiving bicalutamide in combination with LHRH agonists.
Reported in patients treated for prostate cancer.
Rare cases of death or hospitalization because of severe liver injury. Generally occurred within the first 3 to 4 mo of treatment.
Copyright © 2009 Wolters Kluwer Health.